Recent Updates — BHVN
Biohaven Ltd. reported a third-quarter net loss of $129.3 million, or $0.86 per share, compared to a $173.4 million loss in the prior year period. The company announced significant strategic partnerships, including an exclusive global license with SK Biopharmaceuticals for its Kv7 ion channel platform that provides $400 million in near-term cash consideration upon closing, and an exclusive regional license with Ono Pharmaceutical for its MoDE IgG degrader portfolio, yielding up to $100 million in near-term payments. Additionally, the FDA accepted the resubmission of Biohaven's new drug application for Vyglxia (troriluzole) in spinocerebellar ataxia, setting a user fee goal date in the first quarter of 2027. The company operates as a global clinical-stage biopharmaceutical firm focused on discovering and developing therapies for rare and common diseases.
The FDA has accepted Biohaven Ltd.'s resubmitted new drug application (NDA) for troriluzole (Vyglxia) to treat spinocerebellar ataxia (SCA). The agency considers the filing a complete response to its November 4, 2025 action letter and has set a user fee goal date in the first quarter of 2027. The FDA plans to convene an advisory committee meeting to gather external input on the drug's safety and efficacy. Biohaven Ltd. is a clinical-stage biopharmaceutical company focused on developing treatments for neurological disorders.
Biohaven Ltd. entered into a Collaboration and License Agreement with Ono Pharmaceutical Co., Ltd. granting Ono an exclusive, royalty-bearing license to develop and commercialize Biohaven's MoDE pan IgG degrader portfolio, led by BHV-1300, in Japan, South Korea, Taiwan, and ASEAN countries. Under the terms of the agreement, Biohaven will receive a non-refundable upfront payment of $80 million upon closing and an additional $20 million milestone payment contingent on specified stability test results. Ono is responsible for development and commercialization costs in the licensed territory and will pay Biohaven royalties of approximately 20% on net sales. Biohaven retains all rights to the portfolio outside the licensed region, including in the United States, Europe, and China. The company operates as a biopharmaceutical firm focused on immunology, neuroscience, and oncology therapeutics.
Biohaven Ltd. received a partial clinical hold from the FDA on September 4, 2026, pausing new patient enrollment in its BHV-7000 program for refractory focal epilepsy due to insufficient nonclinical data regarding a specific metabolite observed in rodent testing. The hold applies only to new enrollment; dosing continues for over 600 already randomized patients across the program. Study BHV7000-303 is fully enrolled, with topline data expected in the second half of 2026. On August 26, 2026, Biohaven Bioscience Ireland Limited entered into a license agreement with SK Biopharmaceuticals Co., Ltd., granting an exclusive, royalty-bearing worldwide license to its Kv7 ion channel platform, including BHV-7000, pending HSR clearance. The company operates in the biotechnology industry, focusing on developing treatments for neurological disorders.
On August 26, 2026, Biohaven Ltd. entered into a strategic global licensing agreement with SK Biopharmaceuticals Co., Ltd. granting an exclusive worldwide license to its Kv7 ion channel platform, led by opakalim (BHV-7000), for the treatment of focal epilepsy. SKBP will pay a non-refundable upfront fee of $400 million ($350 million at closing and $50 million in 2027) and is eligible to pay up to $150 million in development and regulatory milestones. Biohaven retains rights to conduct ongoing Phase 2/3 clinical trials (RISE 2 and RISE 3) for opakalim, while SKBP assumes responsibility for future development costs and certain milestone obligations totaling $245 million tied to Knopp Biosciences. The transaction includes tiered royalties ranging from the mid-teens to low twenties on U.S. net sales and mid-single-digit royalties on ex-U.S. sales. Biohaven Ltd. is a biopharmaceutical company focused on discovering, developing, and commercializing treatments for immunology, neuroscience, and oncology.
Biohaven Ltd. reported financial results for the second quarter ended June 30, 2026, posting a net loss of $137.3 million, or $0.91 per share, compared to a net loss of $198.1 million in the prior year period. Research and development expenses decreased to $100.8 million from $184.4 million due to strategic reprioritization and lower one-time milestone payments. The company reported cash, cash equivalents, marketable securities, and restricted cash totaling approximately $270.5 million as of June 30, 2026. Clinically, Biohaven initiated a pivotal Phase 3 study for BHV-1300 in Graves' disease and plans to initiate a pivotal Phase 3 trial for BHV-1400 in IgA nephropathy during the second half of 2026. The company also announced new clinical data for its oncology candidate BHV-1530 and completed enrollment in a Phase 2 obesity study for taldefgrobep alfa. Biohaven Ltd. is a global clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for rare and common diseases.